The effects observed on systemic response might be related to treatment schedule; here we determined that anti-NKG2A treatment should start according to its target upregulation on vaccine induced antigen-specific CD8 T cells; however, it was previously reported that different scheduling of anti-PD-1 could have the opposite impact on the efficacy of cancer vaccine in preclinical models [2], while in clinical studies ICB is combined with other immunotherapy using a variety of scheduling. This evidence concerns the gene KLRC1 and cancer.